cancer immunotherapy Archives

Roche hopes blood test will predict immunotherapy efficacy

September 8, 2017

Test could help determine which patients respond to immunotherapies.

Roche hopes blood test will predict immunotherapy efficacy

https://pharmaphorum.com/news/roche-blood-test-immunotherapy/

FDA probes blood cancer immunotherapy safety

September 1, 2017

Regulator reviewing combination therapy safety after issue with Keytruda

FDA probes blood cancer immunotherapy safety

https://pharmaphorum.com/news/fda-looks-cancer-immunotherapy-blood-cancer-safety/

BMS snaps up cancer biotech IFM in $2.3bn deal

August 4, 2017

BMS will gain rights to preclinical cancer immunotherapy drugs.

BMS snaps up cancer biotech IFM in $2.3bn deal

https://pharmaphorum.com/news/bms-ifm-2-3bn-deal/

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

June 14, 2017

Partnerships, co-marketing and the positioning of drugs are shaping the competitive landscape in oncology.

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

https://pharmaphorum.com/views-and-analysis/immunotherapies-oncology-future-cancer/

The week that turned the cancer immunotherapy market on its head

May 12, 2017

Contrasting fortunes for Roche and AZ in a week of drama.

The week that turned the cancer immunotherapy market on its head

https://pharmaphorum.com/news/cancer-immunotherapy/

Pfizer chief suggests no BMS bid – for now

May 4, 2017

Ian Read won’t quash rumours that his company Pfizer could swoop for vulnerable Bristol-Myers Squibb – but says it won’t make any major acquisitions in the

Pfizer chief suggests no BMS bid – for now

https://pharmaphorum.com/news/pfizer-ceo-suggests-bms-swoop-currently-risky/

Sales of Keytruda double ahead of key lung cancer decision

May 3, 2017

FDA to make decision on wider lung cancer use within a week.

Sales of Keytruda double ahead of key lung cancer decision

https://pharmaphorum.com/news/sales-mercks-keytruda-double-ahead-key-lung-cancer-decision/

AZ’s Imfinzi joins the immunotherapy contest

May 2, 2017

AZ hopes for blockbuster sales from Imfinzi.

AZ’s Imfinzi joins the immunotherapy contest

https://pharmaphorum.com/news/fda-approves-azs-durvalumab-immunotherapy-bladder-cancer/

Boehringer looks to cancer immunotherapy combinations

April 7, 2017

BI developing combinations with its own checkpoint inhibitors

Boehringer looks to cancer immunotherapy combinations

https://pharmaphorum.com/news/boehringer-looking-cancer-immunotherapy-combos/

Trending

cancer immunotherapy

Roche hopes blood test will predict immunotherapy efficacy

FDA probes blood cancer immunotherapy safety

BMS snaps up cancer biotech IFM in $2.3bn deal

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

The week that turned the cancer immunotherapy market on its head

Pfizer chief suggests no BMS bid – for now

Sales of Keytruda double ahead of key lung cancer decision

AZ’s Imfinzi joins the immunotherapy contest

Boehringer looks to cancer immunotherapy combinations

CDD for Biologics Summit 2017

Neoantigen Summit 2017

ICI Summit Europe 2017

2nd Annual Cancer Immunotherapy Summit

6th International GMP, GCP & Quality Control Summit

Inhalation and Respiratory Drug Products Summit

NHS seal of approval for gestational diabetes app

Sanofi showcases eczema data ahead of EU decision

COPD triple approved, can GSK maximise its revenues?

Teva sells women’s health division to tackle $35bn debts

EU regulators reject Santhera’s Raxone for DMD

What is ‘affordable’? The reality of the PPRS

UK biotech round-up: Autolus joins CAR-T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit

Get real: virtual reality for healthcare comes of age

Unstable and unpredictable? The reality of the PPRS

Clinical trial summaries for lay people – unpicking the guidance

Search

Advanced Search

Trending

cancer immunotherapy